No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 31 of the 40 quarters in the window, leaving 9 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 46.6x · 10Y median 43.7x · 55th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:36:08.494Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cocrystal Pharma, Inc. (COCP) stock was $1.12 as of Oct 6, 2026, 10:29 AM EDT, up 0.45% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -8.2% · 3-year avg -18.4%/yr · 5-year avg -37.5%/yr
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses.
Biotechnology · Bothell, WA
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.15
Revenue Est.
$105000.00
Last Quarter Results
EPS
$-0.23
vs Estimate
$-0.17
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1COCP | $15.37M | $1.11 | +0.45% | -8.23% | -37.50% | -39.76% | N/A |
| 2KTTA | $15.04M | $0.45 | -1.08% | -42.31% | -61.48% | N/A | vs COCP |
| 3ALLR | $15.75M | $0.99 | -0.99% | -38.75% | N/A | N/A | vs COCP |
| 4BCDA | $15.78M | $1.06 | -2.75% | -19.72% | -61.39% | -46.74% | vs COCP |
| 5KPTI | $14.39M | $0.64 | -5.28% | -89.38% | -62.18% | -41.85% | vs COCP |
| 6BNGO | $16.64M | $1.45 | +0.35% | -24.38% | -78.37% | N/A | vs COCP |
forward FY estimate
N/A
$100000.00
vs Estimate
$50000.00
Consensus Rating
Based on 2 analysts
Average Price Target
$9.00
+707.2% upside
Low
$8.00
Current
$1.11
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.15 | $-0.14 | $-0.13 | 1 |
| Quarter ending Dec 2026 | $-0.15 | $-0.15 | $-0.14 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.73 | $-0.69 | $-0.65 | 1 |
| FY 2027 | $-0.58 | $-0.58 | $-0.58 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $105000.00 | $105000.00 | $105000.00 | 1 |
| Quarter ending Dec 2026 | $105000.00 | $105000.00 | $105000.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| FY 2027 |
| $0.00 |
| $0.00 |
| $0.00 |
| 0 |
